Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.
Oncotarget
Riveiro, Maria E ME; Astorgues-Xerri, Lucile L; Vazquez, Ramiro R; Frapolli, Roberta R; Kwee, Ivo I; Rinaldi, Andrea A; Odore, Elodie E; Rezai, Keyvan K; Bekradda, Mohamed M; Inghirami, Giorgio G; D'Incalci, Maurizio M; Noel, Kay K; Cvitkovic, Esteban E; Raymond, Eric E; Bertoni, Francesco F